zanubrutinib + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone

This combination regimen is a chemoimmunotherapy treatment consisting of the Bruton tyrosine kinase (BTK) inhibitor **zanubrutinib** added to the **Pola-R-CHP** backbone, which includes the antibody-drug conjugate **polatuzumab vedotin**, the anti-CD20 monoclonal antibody **rituximab**, and the chemotherapy agents **cyclophosphamide**, **doxorubicin**, and **prednisone**. It is primarily being investigated as a first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who exhibit high-risk clinical or molecular features, such as the ABC subtype, double-expression of MYC and BCL2, or specific genetic subtypes (e.g., MCD, N1). Zanubrutinib provides targeted inhibition of B-cell receptor signaling, while polatuzumab vedotin delivers a cytotoxic microtubule inhibitor (MMAE) specifically to CD79b-expressing malignant B cells. The addition of zanubrutinib to the Pola-R-CHP regimen aims to enhance efficacy and overcome treatment resistance in high-risk DLBCL populations.

Other names

Zanubrutinib-based combination regimenZanubrutinib + Pola-R-CHP regimen